Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
Mydriasis
Primary: Mean Change in Pupil Diameter — 3.73; 6.46 millimeters
Phase 4 N=11 Wearing-Off Period of Pharmacological Dilation and Anisocoria
Anisocoria
Primary: Number of Participants With Constricting Response to Pilocarpine 1% in the Pharmacologically Dilated Eye — 3 Participants
Phase 4 N=61 Evaluation of Pupil Dilation Speed With the MAP Dispenser
Mydriasis
Primary: Mean Change in Pupil Diameter From Baseline — 4.55; 4.88 millimeters
Phase 3 N=368 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
Mydriasis · Dilation
Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 142; 7; 102; 117 Participants
Phase 3 N=64 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 2.672; 2.583; 2.657; 2.569 millimeters
Phase 4 N=13 The Effect of Brimonidine
Intraocular Pressure
Primary: Intraocular Pressure — 15.4; 16.3; 16.5; 16.7 millimeters of mercury (mmHg)
Phase 3 N=70 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 4.747; 4.779; 0.134; 0.032 millimeters
Phase 2 N=32 Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
Mydriasis · Dilation
Primary: Pupil Diameter (Change From Max) — -1.69; -0.69 mm — p=<0.0001
Phase 3 N=185 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
Mydriasis · Dilation
Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 46; 6 Participants
Phase 3 N=23 Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Mydriasis · Dilation
Primary: Safety Measurements — 0.3; -0.2; 1.6; 0.0 score on a scale
N/A N=28 "Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"
Light Sensitivity
Primary: Heart Rate — 154; 154; 152; 163 Beats per minutes
N/A N=100 Efficacy of the Nanodropper Device on Pupillary Dilation
Dilation
Primary: Spherical Equivalent — -2.62; -2.28; -0.86; -0.55 Diopters — p=0.22
Phase 4 N=28 Intraoperative Floppy Iris Syndrome
Cataract · Floppy Iris Syndrome
Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change
Phase 3 N=405 Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=<0.0001
Phase 4 N=18 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
N/A N=72 Clinical Evaluation of Morcher Artificial Iris Diaphragms
Aniridia · Iris; Deformity
Primary: Change in Light and Glare Sensitivity as Determined by a Clinical Glare Test (Primary Efficacy Measure) — 51; 12; 1 Participants
N/A N=20 Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes
Assess Phenylephrine on EVP and IOP
Primary: Change in Episcleral Venous Pressure (EVP) — 7.2 mmHg — p=<0.01
N/A N=27 The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
Glaucoma, Open-angle · Hypertension, Ocular
Primary: Change in Intraocular Pressure From Baseline at Visit 3 — 21.1; 18.2; 20.0; 17.1 mmHg
Phase 3 N=427 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular…
Phase 2 N=97 Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Myopia
Primary: Axial Length at 36 Months — 25.28; 25.25; 25.33 mm
Phase 3 N=416 Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=0.0001
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Phase 1 N=29 Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201
Myopia
Primary: Number of Unexpected Adverse Events — 41 adverse events
N/A N=71 Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate
Myopia
Primary: Annualized Changes in Refractive Error (SER) — -0.70; -0.66 Dioptre/year
Phase 2 N=24 Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Decrease in Night Vision · Disturbance; Vision, Loss
Primary: Contrast Sensitivity — 0.6; 0.8; 0.9; 0.7 Patches
Phase 4 N=48 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)
Dry Eye
Primary: Sum of the Cooling Scale For Rohto (r) Hydra — 24.6; 12.1 units on a scale
Phase 3 N=10 Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
Opioid Toxicity · Pupillary Miosis · Respiratory Depression
Primary: Area Under the Time Concentration Curve (AUROC ) — 0.9700 Probability
Phase 4 N=43 The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
Phase 3 N=144 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Dim Light Vision Disturbances
Primary: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye — 9; 2 Participants